文献速递自身炎症与 IgG4 相关病

靶向B淋巴细胞清除方案治疗IgG4相关性疾病的研究方案

A protocol for targeted B-lymphocyte depletion for the treatment of IgG4-related disease.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该研究纳入2017年2月至2022年10月在帝国理工学院医疗保健NHS信托确诊的IgG4相关性疾病患者,采用利妥昔单抗靶向B细胞清除至<10个细胞/微升、维持两年的方案。45例接受诱导治疗,所有可评估患者均响应;11/43(26%)发生疾病复发,其中9/11在B细胞重建时发生,复发后再用利妥昔单抗7/7全部有效。

要点

  • 利妥昔单抗靶向B细胞清除至<10个细胞/微升并维持两年,所有可评估患者均获响应。
  • 43例中11例(26%)复发,其中9例在B细胞重建时发生,2例在B细胞未重建时发生。
  • 7例复发后再用利妥昔单抗治疗全部有效。

核心结论

  • 作者认为,利妥昔单抗靶向B细胞清除维持两年是IgG4相关性疾病的有效治疗策略,可限制累积糖皮质激素暴露。
  • 作者指出,复发不常见,通常发生在B细胞重建的情况下,再次给予利妥昔单抗可获得良好的临床响应。

研究设计与样本

  • 研究纳入2017年2月至2022年10月在帝国理工学院医疗保健NHS信托确诊IgG4相关性疾病且首次利妥昔单抗剂量后随访数据>9个月的患者。
  • 利妥昔单抗方案目标为B细胞清除至<10个细胞/微升,维持两年。
  • 利用电子记录定义人口学、血清学和影像学变量,并按IgG4相关性疾病应答指数(RI)评估治疗响应。

主要发现

  • 45例患者接受利妥昔单抗诱导治疗,其中2例随访数据不足无法进行结局分析。
  • 所有患者按IgG4相关性疾病应答指数均对利妥昔单抗治疗有响应。
  • 大多数患者(25/43,58%)在利妥昔单抗诱导时同时接受低剂量糖皮质激素治疗(泼尼松龙中位剂量5毫克/天),其中4/25(16%)在两年时仍使用泼尼松龙(中位剂量5毫克/天)。
  • 疾病复发发生于11/43(26%)患者;9/11例复发发生在B细胞重建时;2/11(18.1%)例复发发生在B细胞未重建时(>10个细胞/微升)。
  • 所有复发后再用利妥昔单抗治疗的患者(7/7,100%)均获得阳性响应。

关键数值与推荐

  • B细胞清除目标为<10个细胞/微升,维持两年。
  • 治疗响应按IgG4相关性疾病应答指数(RI)评估。
  • 复发定义为疾病复发,分为B细胞重建时(>10个细胞/微升)和B细胞未重建时(>10个细胞/微升)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 2例患者因随访数据不足无法进行结局分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the clinical outcomes of patients with immunoglobulin 4-related disease (IgG4-RD) treated with a defined B-cell depletion protocol using rituximab. METHODS: Patients were included if they had (i) an IgG4-RD diagnosis at Imperial College Healthcare NHS Trust between February 2017 and October 2022, and (ii) >9 months of follow-up data available following the first rituximab dose. The rituximab protocol targeted B-cell depletion to <10 cells/microliter for a maintenance period of two years. Electronic records were used to define patient demographics, serological and radiological variables and treatment responses according to the IgG4-RD responder index (RI). RESULTS: Forty-five patients received induction treatment with rituximab. Two patients had insufficient follow-up data for outcome analysis. All patients responded to rituximab therapy according to the IgG4-RD RI. Most patients (25/43, 58%) were also treated with low-dose glucocorticoids at the time of rituximab induction (median prednisolone dose 5 mg daily) and 4/25 (16%) remained on prednisolone at two years (median prednisolone dose 5 mg daily). Disease flares occurred in 11/43 (26%) patients; 9/11 flares occurred in the presence of B-cell repopulation; 2/11 (18.1%) flares occurred in the absence of B-cell repopulation (>10 cells/uL). All flares re-treated with rituximab (7/7, 100%) responded positively. CONCLUSION: Rituximab administration targeting B-cell depletion for a two-year period is an effective treatment strategy for IgG4-RD and can limit the cumulative glucocorticoid exposure. Flares are uncommon and typically occur in the setting of B-cell repopulation, with good clinical responses to further rituximab administration.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Colquhoun M, Barwick TD, Bolton E, et al. A protocol for targeted B-lymphocyte depletion for the treatment of IgG4-related disease. Rheumatology (Oxford). 2025. PMID: 39661482. doi:10.1093/rheumatology/keae675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。